ReviewPsychological medicine2022
Risk for midlife psychosis in women: critical gaps and opportunities in exploring perimenopause and ovarian hormones as mechanisms of risk.
Review in Psychological medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 43 citations in OpenAlex.
- Olanzapine Dosing in Women with First-Episode Psychosis: An Age-Based Proxy for Menopausal Status.Schizophrenia bulletin · 2026Article
- Considerations and practical recommendations for identifying perimenopause in longitudinal research.Psychoneuroendocrinology · 2026Review
- Atractylenolide III Alleviates the Lipid Metabolic Disorders in Ovariectomy-Induced Estrogen-Deficient Mice Through Repairing Intestinal Inflammation and Microenvironment.The journal of obstetrics and gynaecology research · 2026Article
- Global burden for blindness and vision loss among women of childbearing age and perimenopause: age-period-cohort analysis 2021.Scientific reports · 2026Article
- Postmortem tissue biomarkers of menopausal transition.Molecular psychiatry · 2026Article
- Menopause and Mental Health.Advances in therapy · 2026Review
- Schizophrenia.Nature reviews. Disease primers · 2025Review
- Association between parity and female depression: the mediative role of sleep duration.BMC women's health · 2025Article
- Follicle-stimulating hormone: More than a marker for menopause: FSH as a frontier for women's mental health.Psychiatry research · 2025Review
- Prenatal Exposure to MAM Impairs mPFC and Hippocampal Inhibitory Function in Mice during Adolescence and Adulthood.eNeuro · 2024Article
- Exploring causal mechanisms of psychosis risk.Neuroscience and biobehavioral reviews · 2024Review
- The impact of menarche on hippocampal mechanisms of severity of psychotic-like experiences in the ABCD study.Psychoneuroendocrinology · 2024Article
- Sex differences in the functional network underpinnings of psychotic-like experiences in children.bioRxiv : the preprint server for biology · 2024Article
- Sex differences in schizophrenia-spectrum diagnoses: results from a 30-year health record registry.Archives of women's mental health · 2024Article
- Exploring the Intersection of Depression, Anxiety, and Sexual Health in Perimenopausal Women.International journal of women's health · 2024Article
- Epigenetic mechanisms underlying sex differences in the brain and behavior.Trends in neurosciences · 2024Review
- Exploration of first onsets of mania, schizophrenia spectrum disorders and major depressive disorder in perimenopause.Nature. Mental health · 2024Article
- Ovarian Hormones and Binge Eating in Adulthood: Summary of Findings and Implications for Individual Differences in Risk in Women.Current directions in psychological science · 2023Article
- Association between depressive mood and body image and menopausal symptoms and sexual function in perimenopausal women.World journal of clinical cases · 2023Article
- A Sex-Dependent Association Between Doxycycline Use and Development of Schizophrenia.Schizophrenia bulletin · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Women show a heightened risk for psychosis in midlife that is not observed in men. The menopausal transition (i.e. perimenopause) and accompanying changes in ovarian hormones are theorized to account for this midlife increase in risk. This narrative review aims to empirically examine these theories by reviewing studies of midlife and perimenopausal psychosis risk in women and potential ovarian hormone mechanisms of effects. Clinical and pre-clinical studies examining the effects of midlife age, menopausal stage, and ovarian hormones across adulthood on psychosis risk were identified. Synthesis of this body of work revealed that the peak ages of midlife psychosis risk in women overlap with the age range of key menopausal stages (especially the perimenopausal transition), although studies directly assessing menopausal stage are lacking. Studies examining ovarian hormone effects have almost exclusively focused on earlier developmental stages and events (e.g. pregnancy, the menstrual cycle) and show increases in psychotic symptoms in women and female rats during periods of lower estradiol levels. Estrogen treatment also tends to enhance the effects of neuroleptics in females across species at various reproductive phases. Initial data are promising in suggesting a role for menopausal stage and ovarian hormones in psychosis risk. However, critical gaps in our knowledge base remain, as there is a tendency to rely on indirect and proxy measures of menopausal status and hormones. Opportunities for future research are discussed with the goal of increasing research in this critical area of women's health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.